Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ipsen pays Lexicon $23m upfront for ex-US, Japan rights to PhIII drug

This article was originally published in Scrip

Executive Summary

Ipsen of France has signed a deal with Texan firm Lexicon Pharmaceuticals for an exclusive license to commercialize telotristat etiprate outside North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon, which bags $23m upfront under the deal, retains sole rights to commercialize telotristat etiprate in those territories.

Advertisement

Related Content

Meek To Drive M&A At Ipsen, Building On Two Major Launches

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026693

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel